🧭 REBEL Rundown
🔑 Key Points
- 💊 Short vs. standard antibiotic prophylaxis in cirrhotic UGIB: This Bayesian meta-analysis of 14 RCTs (n=1,322) compared shorter courses — including no prophylaxis — against the guideline-recommended 5–7 days in cirrhotic patients with upper GI bleeding.
- 🎯 Non-inferior mortality with shorter or no prophylaxis: Shorter antibiotic courses demonstrated a 97.3% probability of non-inferiority for mortality compared to standard 5–7 day regimens.
- 🦠 Similar rates of rebleeding and bacterial infection: Early rebleeding and infection rates did not meaningfully differ between shorter and standard prophylaxis durations.
- ⚠️ Current guidelines warrant reappraisal: The 5–7 day antibiotic recommendation for cirrhotic UGIB deserves reconsideration — but high-quality RCTs are still needed before practice-changing conclusions can be drawn.
📝 Introduction
Upper gastrointestinal bleeding (UGIB) is a complication in liver cirrhosis patients that can ultimately be life-threatening. There are notable risks of rebleeding, infections and mortality. For many years, the international guidelines recommended 5 to 7 days of prophylactic antibiotics for cirrhotic patients with UGIB. This is based on older trials conducted before major advances that were introduced after 2004, e.a. endoscopic therapies, vasoactive medications, transfusion strategies, and supportive care. 1
However, many of these earlier studies were limited by methodological weaknesses, heterogeneity in infection definitions, and a high risk of bias, raising uncertainty about the true benefit of prolonged prophylaxis.1,2
The authors of this paper sought to compare shorter durations of antibiotic prophylaxis, (including 0 days) with the current recommendation of longer courses via 5–7 days in patients with cirrhosis and upper gastrointestinal bleeding. Their paper also evaluates if shorter antibiotic durations were overall noninferior in preventing all‑cause mortality, early rebleeding, and bacterial infections.
🧾 Paper
Prosty C, et al. Prophylactic Antibiotics for Upper Gastrointestinal Bleeding in Patients With Cirrhosis: A Systematic Review and Bayesian Meta-Analysis. JAMA Internal Medicine. 2025;185(10):1194–1203. PMID: 39271740
Previously Covered On REBEL
⚙️ What They Did
📈 Results:
- Databases searched: Embase, MEDLINE, and CENTRAL.
- Search timeframe: From database inception through September 25, 2024.
- Search terms: Focused on gastrointestinal bleeding and prophylactic antibiotics.
- Study type sought: Randomized clinical trials evaluating antibiotic prophylaxis strategies in patients with cirrhosis and upper gastrointestinal bleeding.
- Initial records identified: 621 records were screened.
- Full-text articles reviewed: 18 articles underwent full-text review.
- Studies included: 14 randomized clinical trials were included in the final systematic review and Bayesian meta-analysis.
- Total participants: 1322 patients were included across the 14 trials.
- Types of comparisons:
- 12 RCTs compared antibiotic prophylaxis with no prophylaxis.
- 2 RCTs compared shorter-duration prophylaxis with longer-duration prophylaxis.
💥 Critical Results
- Shorter and no antibiotic durations showed 97.3% probability of noninferiority for all-cause mortality, compared to longer antibiotic duration
- Absolute risk difference for mortality was within the 5% noninferiority margin: 0.9% (95% CrI: -2.6% to 4.9%)
- Reports showcase a 15.2% increase in bacterial infections via shorter duration antibiotics
- Infection definitions were heterogeneous, ultimately introducing high risk of bias
- There was no reports made of adverse events from antibiotics
- Post-2004 studies regarding modern advancements revealed stronger evidence for noninferiority of shorter antibiotic durations
PRIMARY OUTCOMES:
- All-cause mortality
- Shorter durations, including no prophylaxis, were noninferior to longer durations.
- Events: 83/665 vs 62/657
- Risk difference: 0.9%
- 95% credible interval: −2.6% to 4.9%
- Probability of noninferiority: 97.3%
- Heterogeneity: I² = 40.8%
- Secondary outcome: Early rebleeding
- Shorter durations did not clearly meet noninferiority.
- Events: 91/545 vs 69/544
- Risk difference: 2.9%
- 95% credible interval: −4.2% to 10.0%
- Probability of noninferiority: 73.8%
- Heterogeneity: I² = 71.7%
- Secondary outcome: Bacterial infections
- Shorter durations were associated with more study-defined bacterial infections.
- Events: 182/665 vs 78/657
- Risk difference: 15.2%
- 95% credible interval: 5.0% to 25.9%
- Probability of noninferiority: 2.4%
- Heterogeneity: I² = 83.9%
- Probability of noninferiority: 81.0%
- Adverse events
- No included studies reported adverse events.
- Era-based subgroup: Studies published after 2004
- Probability of noninferiority for mortality increased to 98.9% in post-2004 studies.
- Pre-2004 studies had a lower probability of noninferiority: 72.4%.
- The authors attributed this partly to lower modern baseline mortality and smaller between-group differences.
💪🏽 Strengths
- Clinical Question: The question highlighted in this article is sensible, relevant and defined well. It covers the pressing factors that are central to today’s practice such as standard practice of antibiotics prophylaxis, clinical practice guidelines depending on updated evidence and more
- Randomized Controlled Trials: There was a major focus on RCTs, with 14 total used in this study.
- To increase accuracy, the Cochran Risk of Bias 2 tool was used by reviewers on an independent basis
- Database Search: Comprehensive search via databases like MEDLINE, CENTRAL, Embase was used, lead up to September 25th 2024 in order to gather the most from relevant studies
- Modern Advancements: With advances of upper GI bleed management methods, a subgroup analysis of trials after 2004 was highlighted to look at more current practices.
- Patient-centered Outcomes: this includes all-cause mortality, early rebleeding, and bacterial infections. There is emphasis on actively applying medical decision making decisions
- Transparency of Articles: the selection of articles in this meta-analysis appeared to be reproducible and transparent with their data
- Use of Reviewers for Papers: It is noted that 2 independent reviewers were able to review papers
⚠️ Limitations
- Quality of studies: Cochrane ROB2 model, studies were found to be of low to moderate quality
- Definitions and Terms: Broad definitions used to identify types of infections in the studies; this introduced risk for bias
- Post-2004 Overview: Overview of data from studies prior to 2004 may not reflect modern practices for upper GI bleed management
- Specific Variables and Types: Looking at specific antibiotics, types of bleeds and their sources, management protocols that may guide the clinician to a better decision from a medical standpoint, but was not elaborated in this study. No specific recommendations given overall.
- No Adverse Effects Mentioned: lack of adverse event reports in these studies highlights an overall incomplete analysis, given that there are always side effects to any antibiotic use
- Small Groups to Compare: specifically, comparing longer duration antibiotics which only was highlighted in 2 RCTs vs shorter duration antibiotics via 12 RCTs
- Publication Bias: the funnel plot asymmetry illustrated in this paper is suggestive of this
- Exclusion of Observational Trials: though this potentially increases quality of papers included, it introduces reporting bias
🗣️ Discussion
Heterogeneity:
A major discussion point in this meta-analysis is the heterogeneity across the included trials, seen through the I² statistic; this factor quantifies how much of the variability in effect estimates is due to differences between studies. In this review, heterogeneity arises because the trials vary across variables. This includes antibiotic choice, duration of prophylaxis, infection risk at baseline, upper GI bleeding management, and period of care in which the studies were conducted. These differences may complicate the assumption that all studies are estimating the same underlying treatment effect, making it challenging to gather results confidently or generalize findings to modern practice.
Noninferiority Requires Clinical Judgment
Noninferiority is not entirely statistical. Rather, it shows a value judgment about what difference clinicians and patients are able to accept. Regarding this paper, selecting a small noninferiority margin, e.a. 5%, would be very difficult to meet given the available data, whereas selecting a wider margin makes it easier to conclude that a shorter or alternative strategy is “not worse.” Even when a treatment satisfies the statistical margin, clinical differences may still stand; those differences can influence outcomes such as infection rates, mortality, or antibiotic use with consequences.
Risk of Bias in Infection Outcomes
Bias is a major limitation in this meta-analysis due to infection outcomes being highly susceptible to measurement bias. Several of the included RCTs scored poorly on risk‑of‑bias assessments, raising concerns about reliability of the reported effects. Overall, these issues make it difficult to fully trust or utilize the gathered results, even if there were consistent statistical findings.
Mortality Benefit Is Not Clearly Supported
Another important discussion point is that this meta-analysis challenges the presumed mortality benefit behind current guideline recommendations. The review found a high probability that shorter-duration antibiotics, including no prophylaxis, were noninferior for all-cause mortality. However, this finding should be interpreted with caution because the certainty of evidence was low and several trials had important limitations. This doesn’t prove antibiotics are useless. It implies the evidence of mortality benefit supporting routine 5–7 days of prophylaxis is less robust than what guidelines outline.
Patient Selection May Be the Future Direction
Rather than asking, “should all patients receive antibiotics or not?”, one could ask “which patients with cirrhosis and upper GI bleeding benefit enough from antibiotics to justify the risks?” In higher-risk patients, such as those with advanced cirrhosis, shock, ascites, suspected SBP, ICU-level illness, or high baseline infection risk, may still benefit. Lower-risk patients, especially those with Child-Pugh A disease and controlled bleeding, may be candidates for shorter therapy or no prophylaxis.
📘 Author's Conclusion
“The findings of this systematic review and bayesian meta-analysis do not support the purported mortality benefit driving guideline recommendations for antibiotic prophylaxis in patients with cirrhosis and upper gastrointestinal bleeds. Although prophylaxis reduced reported infections, methodological concerns regarding infection definitions introduced high risk of bias. Higher-quality RCTs are needed to determine the benefit and optimal duration of antibiotic prophylaxis in the modern era of advanced interventions. Until these studies are available, clinicians should be aware that the current guideline recommendations are not based on high-quality evidence.”
💬 Our Conclusion
We support the authors conclusion on needing more RCTs and data to support what would be the preferred period of time to have patients on antibiotic prophylaxis. In a situation where prevention of infection is prioritized (vs prevention of rebleeding), having longer duration of antibiotic use continues to be the current practice. However, the duration of antibiotic administration is still debatable on a case-by-case basis.
🚨 Clinical Bottom Line
This meta-analysis challenges routine 5–7 day antibiotic prophylaxis for all cirrhotic UGIB patients. Shorter courses may be reasonable, especially in lower-risk patients, but the evidence is limited by heterogeneity, bias, poor infection definitions, and lack of harm data.
📚 References
- Prosty et al. 2025
Prophylactic antibiotics for upper gastrointestinal bleeding in patients with cirrhosis: a systematic review and Bayesian meta-analysis. JAMA Intern Med. 2025
PMID: 40788637 - Medical Dialogues 2025
JAMA study questions routine prophylactic antibiotics use for upper‑GI bleeding in cirrhosis. 2025.
Link is Here - Gao et al. 2022
Prophylactic antibiotics on patients with cirrhosis and upper gastrointestinal bleeding: a meta-analysis. PLoS One. 2022;
PMID: 36548353 - Mansoor et al. 2021
Antibiotic prophylaxis for upper gastrointestinal bleed in liver cirrhosis: less may be more. Open Forum Infect Dis. 2021
PMID: 35467310
Post Peer Reviewed By: Marco Propersi DO, (X/IG: @Marco_Propersi) and Mark Ramzy, DO (X/IG: @MRamzyDO)
Meet the Authors
Kevin Tomecsek, MD
Azalia Samsam, DO
🔎 Your Deep-Dive Starts Here
REBEL Core Cast 89.0 – Spontaneous Bacterial Peritonitis
Take Home Points Spontaneous Bacterial Peritonitis (SBP) is a difficult diagnosis to make ...
TEG-Guided Resuscitation of Patients with Cirrhosis and Non-Variceal Bleeding
Background: Thromboelastography (TEG) is a reliable, comprehensive non-invasive hemostatic assay that measures the ...
REBEL Core Cast 39.0 – Upper GI Bleed
Take Home Points Focus on resuscitating well by focusing on the basics Recognize ...
REBEL Cast Ep82: Timing of Endoscopy for UGIB
Background: Upper endoscopy allows for the identification of the source of bleeding as ...
REBEL Core Cast 22.0 – Decompensated Liver Disease
Take Home Points End stage liver disease patients have fragile baseline physiology. ...
